Medicinal Chemistry Research

, Volume 23, Issue 3, pp 1225–1233 | Cite as

Cytotoxic activity assessment and c-Src tyrosine kinase docking simulation of thieno[2,3-b] pyridine-based derivatives

  • Ali Reza Nikkhoo
  • Ramin Miri
  • Nahid Arianpour
  • Omidreza Firuzi
  • Ahmad Ebadi
  • Amir Ahmad Salarian
Original Research

Abstract

Thienopyridine derivatives possess various promising biological properties and particularly cytotoxic effect. In vitro cytotoxic activities of some thienopyridine analogous were evaluated by MTT reduction assay in three human cancer cell lines (HL-60, MCF-7, and LS-180). The compounds showed a wide range of cytotoxic activities and their IC50 values ranged from 0.2 to 100 μM and above. Compound 4e was the most potent derivative and 4i showed good cytotoxic activity against all three cell lines (IC50 <20 μM). Docking simulation of thienopyridine derivatives was implemented on c-Src tyrosine kinase involved in tumor progression and metastases. Results showed that these compounds might potentially bind to the key amino acid Thr339 in the c-Src tyrosine kinase active site. Ligand efficiency (LE) values calculated by using free binding energies obtained from experimental data were predicted by the docking study. Also, experimental and predicted LEs were in good agreement. Based on the LE indices and other findings, some of the thienopyridine derivatives might be efficient candidates for further development as anticancer agents.

Keywords

Thienopyridine Cytotoxic activity Docking simulation Ligand efficiency 

Notes

Acknowledgments

Financial supports of this project by AJA University of Medical Sciences are acknowledged. We gratefully acknowledge the financial support of the Shiraz University of Medical Sciences, vice-chancellor of research.

Reference

  1. Abad-Zapatero C, Metz JT (2005) Ligand efficiency indices as guideposts for drug discovery. Drug Discov Today 10(7):464–469CrossRefPubMedGoogle Scholar
  2. Abdel-Rahman A, Bakhite E, Al-Taifi E (2003) Synthesis and antimicrobial testing of some new S-substituted-thiopyridines, thienopyridines, pyridothienopyrimidines and pyridothienotriazines. Pharmazie 58(6):372–377PubMedGoogle Scholar
  3. Abreu R, Ferreira IC, Calhelha RC, Lima RT, Vasconcelos MH, Adega F, Chaves R, Queiroz M-JR (2011) Anti-hepatocellular carcinoma activity using human HepG2 cells and hepatotoxicity of 6-substituted methyl 3-aminothieno [3, 2-b] pyridine-2-carboxylate derivatives: in vitro evaluation, cell cycle analysis and QSAR studies. Eur J Med Chem 46(12):5800–5806CrossRefPubMedGoogle Scholar
  4. Atatreh N, Stojkoski C, Smith P, Booker GW, Dive C, Frenkel AD, Freeman S, Bryce RA (2008) In silico screening and biological evaluation of inhibitors of Src-SH3 domain interaction with a proline-rich ligand. Bioorg Med Chem Lett 18(3):1217–1222CrossRefPubMedGoogle Scholar
  5. Azizian J, Mohammadi MK, Firuzi O, Razzaghi-asl N, Miri R (2012) Synthesis, biological activity and docking study of some new isatin Schiff base derivatives. Med Chem Res 21(11):3730–3740CrossRefGoogle Scholar
  6. Azizmohammadi M, Khoobi M, Ramazani A, Emami S, Zarrin A, Firuzi O, Miri R, Shafiee A (2013) 2H-chromene derivatives bearing thiazolidine-2,4-dione, rhodanine or hydantoin moieties as potential anticancer agents. Eur J Med Chem 59:15–22. doi:http://dx.doi.org/10.1016/j.ejmech.2012.10.044 Google Scholar
  7. Boschelli DH, Wu B, Barrios Sosa AC, Durutlic H, Ye F, Raifeld Y, Golas JM, Boschelli F (2004) Identification of 7-phenylaminothieno-[3, 2-b] pyridine-6-carbonitriles as a new class of Src kinase inhibitors. J Med Chem 47(27):6666–6668CrossRefPubMedGoogle Scholar
  8. Boschelli DH, Wu B, Barrios Sosa AC, Durutlic H, Chen JJ, Wang Y, Golas JM, Lucas J, Boschelli F (2005) Synthesis and Src kinase inhibitory activity of 2-phenyl-and 2-thienyl-7-phenylaminothieno [3, 2-b] pyridine-6-carbonitriles. J Med Chem 48(11):3891–3902CrossRefPubMedGoogle Scholar
  9. Guarino M (2010) Src signaling in cancer invasion. J Cell Physiol 223(1):14–26PubMedGoogle Scholar
  10. Hopkins AL, Groom CR, Alex A (2004) Ligand efficiency: a useful metric for lead selection. Drug Discov Today 9(10):430CrossRefPubMedGoogle Scholar
  11. Huang H, Ma J, Shi J, Meng L, Jiang H, Ding J, Liu H (2010) Discovery of novel purine derivatives with potent and selective inhibitory activity against c-Src tyrosine kinase. Bioorg Med Chem 18(13):4615–4624CrossRefPubMedGoogle Scholar
  12. Lee K, Kim J, Jeong K-W, Lee KW, Lee Y, Song JY, Kim MS, Lee GS, Kim Y (2009) Structure-based virtual screening of Src kinase inhibitors. Bioorg Med Chem 17(8):3152–3161CrossRefPubMedGoogle Scholar
  13. Litvinov V, Dotsenko V, Krivokolysko S (2005) Thienopyridines: synthesis, properties, and biological activity. Russ Chem Bull 54(4):864–904CrossRefGoogle Scholar
  14. Liu K, Rao W, Parikh H, Li Q, Guo TL, Grant S, Kellogg GE, Zhang S (2012) 3,5-Disubstituted-thiazolidine-2,4-dione analogs as anticancer agents: design, synthesis and biological characterization. Eur J Med Chem 47:125–137CrossRefPubMedGoogle Scholar
  15. Miri R, Motamedi R, Rezaei MR, Firuzi O, Javidnia A, Shafiee A (2011) Design, synthesis and evaluation of cytotoxicity of novel chromeno [4, 3-b] quinoline derivatives. Arch Pharm (Weinheim) 344(2):111–118CrossRefGoogle Scholar
  16. Mitra SK, Schlaepfer DD (2006) Integrin-regulated FAK–Src signaling in normal and cancer cells. Curr Opin Cell Biol 18(5):516–523CrossRefPubMedGoogle Scholar
  17. Morris GM, Huey R, Lindstrom W, Sanner MF, Belew RK, Goodsell DS, Olson AJ (2009) AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility. J Comput Chem 30(16):2785–2791PubMedCentralCrossRefPubMedGoogle Scholar
  18. Morwick T, Berry A, Brickwood J, Cardozo M, Catron K, DeTuri M, Emeigh J, Homon C, Hrapchak M, Jacober S (2006) Evolution of the thienopyridine class of inhibitors of IκB kinase-β: part I: hit-to-lead strategies. J Med Chem 49(10):2898–2908CrossRefPubMedGoogle Scholar
  19. Mosmann T (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65(1):55–63CrossRefPubMedGoogle Scholar
  20. Noronha G, Barrett K, Cao J, Dneprovskaia E, Fine R, Gong X, Gritzen C, Hood J, Kang X, Klebansky B (2006) Discovery and preliminary structure–activity relationship studies of novel benzotriazine based compounds as Src inhibitors. Bioorg Med Chem Lett 16(21):5546–5550CrossRefPubMedGoogle Scholar
  21. Pengetnze Y, Steed M, Roby KF, Terranova PF, Taylor CC (2003) Src tyrosine kinase promotes survival and resistance to chemotherapeutics in a mouse ovarian cancer cell line. Biochem Biophys Res Commun 309(2):377–383CrossRefPubMedGoogle Scholar
  22. Penthala NR, Yerramreddy TR, Crooks PA (2010) Microwave assisted synthesis and in vitro cytotoxicities of substituted (Z)-2-amino-5-(1-benzyl-1H-indol-3-yl) methylene-1-methyl-1H-imidazol-4 (5H)-ones against human tumor cell lines. Bioorg Med Chem Lett 20(2):591–593PubMedCentralCrossRefPubMedGoogle Scholar
  23. Pevet I, Brulé C, Tizot A, Gohier A, Cruzalegui F, Boutin JA, Goldstein S (2011) Synthesis and pharmacological evaluation of thieno [2, 3-b] pyridine derivatives as novel c-Src inhibitors. Bioorg Med Chem 19(8):2517–2528CrossRefPubMedGoogle Scholar
  24. Queiroz M-JR, Calhelha RC, Vale-Silva LA, Pinto E, Lima RT, Vasconcelos MH (2010) Efficient synthesis of 6-(hetero) arylthieno [3, 2- b] pyridines by Suzuki–Miyaura coupling. Evaluation of growth inhibition on human tumor cell lines, SARs and effects on the cell cycle. Eur J Med Chem 45(12):5628–5634CrossRefPubMedGoogle Scholar
  25. Saito K, Nakao A, Shinozuka T, Shimada K, Matsui S, Oizumi K, Yano K, Ohata K, Nakai D, Nagai Y, Naito S (2013) Discovery and structure-activity relationship of thienopyridine derivatives as bone anabolic agents. Bioorg Med Chem 21(7):1628–1642. doi: 10.1016/j.bmc.2013.01.071 CrossRefPubMedGoogle Scholar
  26. Salarian AA, Asadi-Eskandar A, Sakhteman A, Abdi K (2012) Synthesis and docking studies of some 3-amino-6-(thiophen-2-yl)thieno[2, 3-b]pyridine derivatives. Asian J Chem 25(3):1275–1278Google Scholar
  27. Schnute ME, Cudahy MM, Brideau RJ, Homa FL, Hopkins TA, Knechtel ML, Oien NL, Pitts TW, Poorman RA, Wathen MW (2005) 4-Oxo-4,7-dihydrothieno [2, 3-b] pyridines as non-nucleoside inhibitors of human cytomegalovirus and related herpesvirus polymerases. J Med Chem 48(18):5794–5804CrossRefPubMedGoogle Scholar
  28. Shah YM, Rowan BG (2005) The Src kinase pathway promotes tamoxifen agonist action in Ishikawa endometrial cells through phosphorylation-dependent stabilization of estrogen receptor α promoter interaction and elevated steroid receptor coactivator 1 activity. Mol Endocrinol 19(3):732–748CrossRefPubMedGoogle Scholar
  29. Shirey JK, Xiang Z, Orton D, Brady AE, Johnson KA, Williams R, Ayala JE, Rodriguez AL, Wess J, Weaver D (2007) An allosteric potentiator of M4 mAChR modulates hippocampal synaptic transmission. Nat Chem Biol 4(1):42–50CrossRefPubMedGoogle Scholar
  30. Thaimattam R, Daga PR, Banerjee R, Iqbal J (2005) 3D-QSAR studies on c-Src kinase inhibitors and docking analyses of a potent dual kinase inhibitor of c-Src and c-Abl kinases. Bioorg Med Chem 13(15):4704–4712CrossRefPubMedGoogle Scholar
  31. Trujillo JI (2011) MEK inhibitors: a patent review 2008–2010. Expert Opin Ther Pat 21(7):1045–1069CrossRefPubMedGoogle Scholar
  32. Wallace AC, Laskowski RA, Thornton JM (1995) LIGPLOT: a program to generate schematic diagrams of protein-ligand interactions. Protein Eng 8(2):127–134CrossRefPubMedGoogle Scholar
  33. Youssefyeh RD, Brown RE, Wilson J, Shah U, Jones H, Loev B, Khandwala A, Leibowitz MJ, Sonnino-Goldman P (1984) Pyrido [3’, 2’: 4, 5] thieno [3, 2-d]-N-triazines: a new series of orally active antiallergic agents. J Med Chem 27(12):1639–1643CrossRefPubMedGoogle Scholar
  34. Zeng X–X, Zheng R-L, Zhou T, He H-Y, Liu J-Y, Zheng Y, Tong A-P, Xiang M-L, Song X-R, Yang S-Y (2010) Novel thienopyridine derivatives as specific anti-hepatocellular carcinoma (HCC) agents: synthesis, preliminary structure–activity relationships, and in vitro biological evaluation. Bioorg Med Chem Lett 20(21):6282–6285CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  • Ali Reza Nikkhoo
    • 1
    • 2
    • 3
  • Ramin Miri
    • 2
    • 3
  • Nahid Arianpour
    • 1
  • Omidreza Firuzi
    • 2
  • Ahmad Ebadi
    • 2
    • 3
  • Amir Ahmad Salarian
    • 1
  1. 1.Department of ToxicologyAJA University of Medical ScienceTehranIran
  2. 2.Medicinal & Natural Products Chemistry Research CenterShiraz University of Medical SciencesShirazIran
  3. 3.Department of Medicinal Chemistry, School of PharmacyShiraz University of Medical SciencesShirazIran

Personalised recommendations